SCF Ethnobioprospecting Workflow Initiated
Program Focus: Ammonia Modulators for Hepatic Encephalopathy
Program Codename: PROJECT AMMONEX-HE
Therapeutic Aim: Gut–liver–brain ammonia modulation for hepatic encephalopathy.
Regulatory Scope: Research → Discovery → Preclinical → Pre-IND → IND/FIH readiness.
Clinical comparator logic: current HE standards reduce ammonia burden through lactulose and rifaximin-based gut ammonia control; rifaximin is FDA-indicated to reduce overt HE recurrence in adults.
1. SCF Disease Target Definition
Target Layer | HE-Ammonia Fault Node | SCF Therapeutic Objective |
Gut microbiome | Urease-producing bacteria, dysbiosis | Reduce ammonia generation |
Intestinal barrier | Endotoxemia, inflammatory permeability | Restore mucosal containment |
Liver | impaired urea-cycle clearance | Support nitrogen handling |
Blood-brain axis | astrocyte glutamine/osmotic stress | Reduce neurotoxic ammonia signaling |
Systemic inflammation | TNF-α, IL-6, oxidative stress | Lower neuroinflammatory amplification |
2. SCF Ethnobioprospecting Search Parameters
Search Domain | Priority Source Systems | Candidate Logic |
Hepatoprotective ethnomedicine | Ayurveda, TCM, Amazonian, MENA, African systems | liver detoxification, bile flow, anti-inflammatory use |
Gut ammonia modulation | bitter tonics, antimicrobial botanicals, prebiotic botanicals | microbiome ammonia reduction |
Neuroprotection | adaptogens, flavonoids, polyphenols | astrocyte and neuroimmune stabilization |
Safety harmonization | mucosal protectants, antioxidants | cirrhosis-compatible tolerability |
This follows SCF botanical selection, authentication, extraction, MoA/MeA profiling, PK/metabolic profiling, and role assignment logic.
3. Initial Candidate Classes
SCF Role | Candidate Bioactive Class | Rationale |
Target Modulator | urease-inhibitory polyphenols / tannins | reduce gut ammonia production |
Metabolic Regulator | lignans, saponins, AMPK/SIRT-modulating compounds | support hepatic metabolic resilience |
Safety Harmonizer | mucilage, β-glucans, hepatoprotective flavonoids | protect gut barrier and reduce inflammation |
Absorption Enhancer | lipid carriers, phospholipid complexes | improve exposure while limiting systemic toxicity |
Resistance Prevention | multi-compound antimicrobial–anti-inflammatory stack | avoid single-target microbiome pressure |
4. Priority Ethnobioprospecting Leads
Candidate Source | Bioactive Focus | SCF Development Rationale |
Phyllanthus niruri | lignans, flavonoids | hepatoprotective and liver-metabolic candidate |
Silybum marianum | silymarin flavonolignans | hepatic antioxidant/safety harmonizer |
Curcuma longa | curcuminoids | NF-κB / inflammatory tone modulation |
Cichorium intybus | inulin, bitter sesquiterpenes | prebiotic gut ammonia-axis modulation |
Terminalia chebula | tannins/polyphenols | possible urease/gut microbial modulation |
Ganoderma spp. | β-glucans, triterpenes | immune and gut-barrier harmonization |
Genipa americana | iridoids | Amazonian hepatoprotective lead from available SCF database. |
5. Proposed SCF Fibonacci Ammonia-Modulator Stack
Stack Position | Role | Development Candidate Type |
F1 | Primary ammonia modulator | urease-inhibitory polyphenol fraction |
F1 | Safety harmonizer | hepatoprotective flavonolignan |
F2 | Metabolic stabilizers | AMPK/SIRT and antioxidant compounds |
F3 | Gut-axis optimizers | prebiotic fiber, mucosal protectant, microbiome modulator |
F5 | Supportive agents | anti-inflammatory, bile-flow, redox, neuroprotective, barrier-support agents |
6. Discovery Assay Plan
Assay Module | Endpoint |
Urease inhibition | IC50 against bacterial urease |
Ammonia production model | ammonia reduction in gut fermentation model |
Hepatocyte protection | oxidative stress, mitochondrial function, urea-cycle gene expression |
Gut barrier model | TEER, tight-junction proteins, LPS translocation |
Neurotoxicity model | astrocyte swelling, glutamine accumulation, inflammatory markers |
Microbiome safety | dysbiosis risk and antimicrobial spectrum |
7. SCF Synergy Metrics
Metric | Use |
TSSM | potency × precision × persistence |
HSV-F² | metabolic efficiency and signal coherence |
SV-EQ | target specificity versus diffuse activity |
MGIS | ligand–target and PK geometry |
SPCI | translational compatibility and phenotype fit |
These align with the SCF Synergistic Evaluation Framework.
8. FDA-Aligned Preclinical Pathway
Stage | Required Output |
Discovery | lead fractions, molecular fingerprints, MoA/MeA |
Lead optimization | standardized extract or purified/semi-synthetic API |
IND-enabling | pharmacology, ADME, GLP toxicology, safety pharmacology |
CMC | identity, potency assay, stability, contaminants, batch reproducibility |
Pre-IND | FDA meeting package |
IND | nonclinical, CMC, and FIH protocol package |
FDA IND submissions require adequate preclinical data, CMC, investigator information, and clinical protocols; botanical candidates should also follow FDA botanical drug development expectations when applicable.
Immediate GPT Trigger Commands
Trigger | GPT Action |
Disease Map | Build HE ammonia fault architecture |
Source Scan | Identify ethnomedical ammonia-modulator candidates |
Lead Rank | Rank candidates by SCF potency and safety |
Assay Plan | Generate in vitro and ex vivo screening matrix |
Stack Build | Design SCF Fibonacci ammonia-modulator stack |
IND Map | Build FDA preclinical-to-IND roadmap |
Next Command
Use “Lead Rank” to generate the first ranked candidate table for PROJECT AMMONEX-HE.
INDEX
SCF-ETHBIO-HE-AMM-0001 — Ethnobioprospecting Initiation
SCF-AMMONEX-HE-0001 — Ammonia Modulator Program
SCF-SEF-HE-0001 — Synergy Evaluation Pathway
SCF-IND-HE-0001 — Preclinical-to-IND Alignment